By Kamal Choudhury March 16 (Reuters) - Rhythm Pharmaceuticals said on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial.

By Michele Gershberg and Michael Erman PHILADELPHIA, March 16 (Reuters) - The CEO of Roche's Genentech unit, Ashley Magargee, ...

Eli Lilly and Co on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12. The company said internal testing detected ...

Regeneron’s Chinese partner reported Zepbound-like efficacy in a phase 3 trial, de-risking one part of the Big Biotech’s differentiated play for the obesity market.

Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

Eli Lilly warns compounded tirzepatide mixed with B12 may contain impurities and safety risks as FDA tightens GLP-1 rules—get the latest updates now.

Copenhagen-based Zealand Pharma, the biotech working on a slate of obesity drug candidates, is planting a new research hub in ...

Eli Lilly CFO Lucas ‌Montarce said on Monday it is preparing to launch its new ⁠oral obesity drug, orforglipron, ​in the United States ⁠as early as the second quarter of this ‌year.

California says it leads with science and compassion. By cutting treatment for chronic obesity, it is doing the opposite. If ...

“Tolerability is going to be king as long as you can provide the weight loss that the individual patient is looking for.” ...

Obesity is increasingly referred to as a chronic disease. This is also how it is defined in the recommendations of scientific ...

This week, Mad in America examines three studies around mental health diagnosis, psychotropic drug use, obesity, and diabetes ...